Recently, the Phase II CITYSCAPE (NCT03563716) trial evaluated the possible efficacy of combining tiragolumab with anti–PD-1 antibody atezolizumab in the first-line treatment of NSCLC with PD-L1 expression >1%, assessed by means of the tumor proportion score (TPS). The gene discussed is CD274; the disease is neoplasm.